ABSTRACT
INTRODUCTION
Experimental evidence suggests that therapeutic strategies targeting MDSCs may be beneficial in cancer therapy (11) (12) (13) (14) (15) . Studies show that modulation of recruitment, differentiation, and expansion of myeloid cells could promote antitumor immunity and block tumor progression (11) (12) (13) (14) (15) . Strategies targeting the mCSF1 receptor (CSF1R), the CCL2 receptor (CCR2), or PI3K
reduce tumor growth and inflammation in animal models and are currently undergoing testing in cancer patients (11) (12) (13) (14) . We previously found that CD11b + Gr1 + monocyte and granulocyte trafficking to tumors from circulation depends on PI3K-mediated activation of integrin  4 β 1 , a receptor for endothelial cell VCAM (14) (15) (16) (17) (18) . As the most prevalent PI3K isoform in normal myeloid cells, PI3K is also required for neutrophil motility and trafficking during inflammatory disease (19) (20) . We found that numerous cytokines and chemokines activate PI3K including SDF-1, VEGF-A, IL4, IL6, and CSF1 (17) . Once activated, PI3K stimulates BTK, PLC, RAPGEF, Rap1a, RIAM, and paxillin-dependent integrin  activation (14) (15) (16) (17) (18) . Inhibition of PI3K, BTK, PLC, RAPGEF, Rap1a, RIAM, or integrin     suppresses monocyte and granulocyte accumulation in tumors and inhibits tumor growth (14) (15) (16) (17) (18) .
PI3Kγ not only controls myeloid cell trafficking during tumor growth and inflammation, but also controls myeloid cell polarization by regulating immune suppressive gene expression in tumor associated macrophages, monocytes and granulocytes (21) (22) . Our studies showed that PI3K stimulates mTor, S6K and C/EBP-mediated anti-inflammatory gene expression and inhibits NFB-mediated pro-inflammatory gene expression, thereby promoting expression of immune suppressive factors, such as IL10, TGF, and Arginase, and inhibiting expression of IL12, IFN and Nos2 (21) (22) . PI3K activity thereby suppresses T-cell immunity and stimulates tumor growth (21) . Since our prior studies showed that PI3Ksignaling activates integrin     to promote myeloid cell adhesion and invasion, we speculated that integrin     might also regulate myeloid cell polarization downstream of PI3K and thereby affect the antitumor immune response.
We show here that integrin   β 1 promotes immune suppressive myeloid cell polarization, inhibits antitumor immunity and stimulates tumor growth. Genetic or pharmacologic blockade of integrin   β 1 or its activator PI3Kγ inhibits immunosuppressive myeloid cell polarization, stimulates dendritic cell maturation and restores antitumor T cell-mediated immunity in mouse Panc02 pancreatic tumor were initiated by implanting 1 x 10 6 Panc02 pancreatic carcinoma cells into the pancreas of syngeneic mice (n = 8-10). The abdominal cavities of immunocompetent C57Bl/6J mice, integrin α4Y991A mutant and PI3K -/-mice were opened and the tails of the pancreas were exteriorized. One million Panc02 cells were injected into the pancreatic tail, the pancreas was placed back into the abdominal cavity, and the incision was closed. Pancreas were excised and cryopreserved after 5 weeks. Tumor weight and immune cell infiltration were quantified as described.
Drug treatment of tumors
Studies with blocking mAb to integrin  4 : C57Bl/6J mice were subcutaneously implanted on day 
Isolation of bone marrow derived cells for bone marrow transplantation
Bone marrow cells were aseptically harvested from 6-8 week tumor growth in C57BL/6 and 4Y991A mice transplanted with BM from 4Y991A or WT were compared as described above. Tumors were isolated, minced and digested to single cell suspension for 1 h at 37
Isolation of tumor-infiltrating immune cells
• C in 5ml of Hanks Balanced Salt Solution (HBSS, Invitrogen) containing 1 mg/ml collagenase type IV (Sigma), 0.1 mg/ml hyaluronidase (Sigma) and 20 U/ml DNase type IV (Sigma). Cell suspensions were filtered through a 70 μm cell strainer and then incubated with different antibodies to perform flow cytometry.
Flow cytometry
Tumor-infiltrating immune cells were incubated with Fc-blocking reagent (anti CD16/CD32, BD 
Analysis of gene expression

Immunohistochemistry
Tumor samples were collected and progressively frozen in cold 2-methylbutane solution.
Sections (6 μm) were fixed in 100% cold acetone, blocked with 8% normal goat serum for 2 hours, and incubated with the appropriate primary antibodies (rat anti-mouse CD11b, Hamster anti-mouse CD11c, rat anti-mouse CD8a or rat anti-mouse CD11b, BD Biosciences) for 2 hours at room temperature. Sections were washed 3 times with PBS and incubated with goat anti-rat secondary antibodies coupled to Alexa488 or 597 for CD11b, CD8 and CD4 studies or with Cy5-goat anti-Hamster for CD11c studies. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). The slides were washed and mounted in DAKO fluorescent mounting medium. The detection of apoptotic cells was performed using a TUNEL-assay (ApoTag Fluorescein In Situ Apoptosis Detection Kit, Promega) in accordance with the manufacturer's instructions.
Immunofluorescence images were collected on a Nikon microscope (Eclipse TE2000-U) and pixels of fluorescence or area of staining was quantified using MetaMorph Software.
Isolation of tumor-infiltrating myeloid cells and T cells
Myeloid CD11b
+ cells and CD90.2 + (Thy1.2) T cells were isolated from tumor cell suspensions using CD11b or CD90.2 microbeads (Miltenyi Biotech), respectively. The purity of the sorted cells was typically >80% as assessed by FACS analysis. In some experiments, tumor-infiltrating lymphocytes were stained with CD4-FITC (GK1.5, eBioscience) and CD8-APC (53-6.7, eBioscience).
In vitro cytotoxicity assay
Thy1. 
Effect of T cells from mice bearing tumors on tumor cell killing in vivo
CD90.2 + T cells were first isolated from the spleens of WT, α4Y991A and PI3Kγ -/-mice bearing tumors using the MACS system and then mixed with viable LLC tumor cells at ratio 1:2. The mixture was injected into the flanks of naïve mice. Tumor growth, intratumoral apoptosis and necrosis were investigated after 10 days.
IL10 Elisa
Tumors were collected and homogenized in RIPA lysis buffer (137mM NaCl, 20mM Tris-HCL pH8, 10% Glycerol, 1% Triton X-100, 0.1% SDS and protease inhibitor cocktail). Protein extracts were clarified by centrifugation at 12,000 g for 10 minutes at 4°C, and clarified protein samples were used for IL10 ELISA quantification (R&D Systems).
Statistical Analysis
Results were expressed as mean ± SEM. Data comparing differences between two groups were assessed using unpaired Student's t-test. One-way ANOVA with post hoc testing was used for 12 multiple comparisons. A value of P < 0.05 was considered significant. (Fig. 1) . Integrin α4Y991A mice express a knock-in point mutation in the   cytoplasmic tail that inhibits integrin activation, which is controlled by PI3Kγ signaling in myeloid cells (17) . LLC and Panc02 tumors implanted in integrin 4Y991A and PI3K -/-mice were both significantly smaller than tumors implanted in control treated mice (P < 0.001), whether analyzed at endpoint or over time (Fig. 1A-C) . Growth of lung 4) or TG100-115, a PI3K inhibitor (Fig. 1A, Supplementary Fig.   S1 ). Flow cytometric analyses of LLC or Panc02 tumors implanted in WT, integrin 4Y991A and
PI3K
-/-mice revealed significant (P < 0.01) reductions in infiltration of total CD11b + Gr1 + myeloid cells (Fig. 1D-F were observed in tumor-bearing mice treated with the anti-α4 or with the PI3Kγ inhibitor TG100-115 ( Fig. 1D-G) . These data show that loss of PI3K or integrin  4 activity affects trafficking of Gr1 + but not Gr1 -myeloid cells.
Tumors from PI3K -/-and 4Y991A animals not only exhibited decreased CD11b + cell infiltration but also increased CD11c + dendritic cell infiltration in tumors and lymph nodes compared to control animals ( Fig. 2A-C) . Similar results were observed in Y991A mice transplanted with 4Y991A bone marrow but not in mice transplanted with WT bone marrow ( Fig. 2D-F) . The percentages of mature MHCII-expressing dendritic cells (CD11c
increased in α4Y991A and PI3Kγ -/-Panc02 and LLC tumors compared to WT tumors (P < 0.01) and in tumors from animals that were treated with anti-α4 or the PI3Kγ inhibitor TG100-115
( Fig. 2G-I ). The ratio of MHCII + mature DC to MHCII -immature DC was 2-fold higher in tumors from these mice compared to control mice (P < 0.001) (Fig. 2J-K) . In addition, levels of the co- 
stimulatory protein CD80 were significantly (P < 0.05) higher in dendritic cells in tumors from
-/-and Y991A animals (Fig. 2L) . Together, these results indicate that PI3K and  4 integrin inhibit dendritic cell recruitment and maturation in association with tumor inflammation and growth and that inhibitory targeting of these molecules can stimulate dendritic cell recruitment and activation.
Integrin and PI3K -/-mice ( Fig. 3A-B) . Treatment of LLC tumors with anti-α 4 or the PI3Kγ inhibitor (TG100-115) had similar effects on inflammatory factor expression ( Fig. 3C-D) . These gene expression changes were also observed in tumor associated CD11b + myeloid cells purified from 4Y991A and PI3K -/-mice (Fig. 3E ).
To determine whether integrin  4  1 like PI3K controls macrophage polarization, we also 
performed gene expression analyses on in vitro cultured, IL4-stimulated macrophages derived from bone marrow of WT and 4Y991A mice. We found that loss of integrin activity in  4 Y991A macrophages suppressed expression of Il10, Arg1, and Tgfb1 and stimulated expression of mRNAs encoding immune stimulatory factors such as IL12 and IFN in vitro (Fig. 3F) (Fig. 4D-F ). Mice treated with blocking mAbs to IL10 exhibited increased expression of Il12b, Ifng, and Cd8a mRNA (Fig. 4G-I ) as well as increased infiltration of CD8 + T cells as detected by IHC (Fig. 4J-K) . Together, these data suggest that the 
PI3Kγ-integrin  4 pathway inhibited CD8 + TIL recruitment and activation
To promote an effective antitumor immune response, tumor-specific T cells must be present in sufficient numbers to kill their targets. A direct correlation exists between the number of tumor-infiltrating lymphocytes (TILs) and a favorable clinical outcome (23) (24) (25) (26) . Furthermore, the functional status of TILs has been correlated with a favorable prognosis in human malignancies (25) (26) . To further understand the mechanisms underlying the immune suppression mediated by inhibition of the PI3K-integrin  4 pathway, we evaluated whether blockade of this pathway alters both the number and the activation state of the tumor-infiltrating lymphocytes.
Histological examination of tumors revealed reduced numbers of CD4 + T cells and increased numbers of CD8 + T cells in tumors from both 4Y991A and PI3Kγ -/-mice when compared to WT mice ( Fig. 5A-B) . Additionally, flow cytometric analysis of tumor-infiltrating lymphocytes isolated from tumors showed that numbers of CD4 + T cells were reduced, whereas numbers of CD8 + T cells were increased, in α4Y991A and PI3K -/-mice compared to WT mice ( Fig. 5C-D) .
These observations were supported by increases in total Cd8a mRNA in tumors from both 4Y991A and PI3Kγ -/-mice when compared to WT mice (Fig. 5E ). TILs from α4Y991A and PI3K 
Finally, the PI3K-integrin  4 pathway also affects tumor progression by promoting angiogenesis (17) . Myeloid cells can support tumor angiogenesis and growth through the production of proangiogenic factors (28) (29) (30) (31) (32) . We found that blockade of the PI3Kγ-integrin  4 pathway reduced expression of proangiogenic factors and tumor angiogenesis. Inhibition of this pathway increased myeloid cell expression of IL12, an anti-angiogenic Th1 cytokine (33) (34) .
Therefore, inhibition of PI3K and integrin  controls both tumor angiogenesis and immunity.
Inhibition of the PI3Kγ-  integrin pathway could also influence development of regulatory T cells (Treg), which maintain tumor immune tolerance (34) . In fact, we found that TGF, a cytokine that induces the generation of Treg (35) 
